Table 2.
Changes in the serum hormone levels in prostate cancer patients treated with a luteinizing hormone-releasing hormone agonist
| PRE | 6MO | 12MO | Statistics | ||
|---|---|---|---|---|---|
| T | Mean (ng/dL) | 378.8 ± 145.1 | 9.6 ± 5.0 | 7.7 ± 4.6 | P < 0.01 PRE vs, 12MO |
| Percentile change | -97.5% | -98.0% | |||
| DHT | Mean (pg/mL) | 420.2 ± 200.2 | 21.6 ± 12.2 | 20.8 ± 11.2 | P < 0.01 PRE vs 6MO, 12MO |
| Percentile change | -94.9% | -95.0% | |||
| E2 | Mean (pg/mL) | 16.2 ± 5.2 | 1.3 ± 1.0 | 1.4 ± 1.0 | p < 0.01 PRE vs 6MO, 12MO |
| Percentile change | -92.2% | -91.3% | |||
| DHEA-S | Mean (μg/dL) | 144.9 ± 66.6 | 107.2 ± 48.6 | 103.5 ± 54.3 | P < 0.01 PRE vs 6MO, 12MO |
| Percentile change | -26.1% | -28.6% | |||
| DHEA | Mean (ng/mL) | 1.85 ± 0.91 | 1.38 ± 0.67 | 1.29 ± 0.65 | P < 0.01 PRE vs 6MO, 12MO |
| Percentile change | -25.1% | -30.0% | |||
| A-dione | Mean (pg/mL) | 384.0 ± 133.5 | 231.7 ± 109.4 | 227.8 ± 119.7 | p < 0.01 PRE vs 6MO, 12MO |
| Percentile change | -39.7% | -40.7% | |||
| cortisol | Mean (ng/mL) | 89.9 ± 26.7 | 94.9 ± 27.4 | 81.4 ± 23.4 | Not significant |
| Percentile change | 5.4% | -10.4% |
PRE: pretreatment 6MO: 6 months after initiation of LH-RH agonist treatment.
12MO: 12 months after initiation of LH-RH agonist treatment.
T: testosterone, DHT: dihydrotestosterone, E2; estradiol, DHEA-S: dehydroepiandrosterone-sulfate.
DHEA: dehydroepiandrosterone.
Percentile change: changes in comparison with pretreatment levels.
The percentile change is in comparison with the pretreatment levels. Values are expressed as means ± SD (standard deviation).